Patient dies in China biotech company’s gene editing trial

• In a statement Wednesday, the treatment’s developer, Shanghai-based HuidaGene Therapeutics, attributed the Aug 2025 death to acute respiratory distress syndrome as part of a severe immune reaction to the therapy.